Swiss drugmaker Roche has entered into a collaboration and licensing agreement with China's Hansoh Pharmaceutical Group to develop a portfolio of antibody-drug conjugate programs for multiple cancer types. Under the October 19, 2026 agreement, Hansoh receives $400 million upfront and $110 million after one year, with potential milestone payments exceeding $15 billion. Hansoh leads early development through Phase Ia trials, while Roche holds commercial rights outside Greater China.
Scope and Significance of the deal
- ▪On October 19, 2026, Swiss drugmaker Roche entered into a collaboration and licensing agreement with China's Hansoh Pharmaceutical Group covering a portfolio of antibody-drug conjugate programs for multiple cancer types
- ▪The October 2026 licensing deal with Hansoh Pharmaceutical Group marks one of the largest cross-border biopharmaceutical drug discovery collaborations of the year for Roche
Financial terms of the agreement
- ▪Hansoh Pharmaceutical Group will receive an upfront payment of $400 million from Roche under the October 19, 2026 licensing agreement
- ▪Hansoh Pharmaceutical Group is scheduled to receive a first anniversary payment of $110 million from Roche one year after signing the October 19, 2026 agreement
- ▪The October 19, 2026 agreement between Roche and Hansoh Pharmaceutical Group carries a total potential value exceeding $15 billion through milestone payments
- ▪Hansoh Pharmaceutical Group is eligible to receive royalties on commercial sales if the antibody-drug conjugate products from the October 19, 2026 Roche deal reach the market
Development responsibilities and territorial rights
- ▪Hansoh Pharmaceutical Group retains rights to develop, register, and sell a portfolio of antibody-drug conjugate programs in mainland China, Hong Kong, Macau, and Taiwan, with an option to co-develop up to two programs outside those territories
- ▪Under the October 19, 2026 agreement, Hansoh Pharmaceutical Group will lead the early development of a portfolio of antibody-drug conjugate programs until global Phase Ia clinical trials are complete
Story comments
Loading comments…